Search

Your search keyword '"Yoon, Sung‐Soo"' showing total 2,643 results
Start Over Author "Yoon, Sung‐Soo"
2,643 results on '"Yoon, Sung‐Soo"'

6. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.

Author

Martinelli, Giovanni, Neubauer, Andreas, Sierra, Jorge, Montesinos, Pau, Recher, Christian, Yoon, Sung-Soo, Maeda, Yoshinobu, Hosono, Naoko, Onozawa, Masahiro, Kato, Takayasu, Kim, Hee-Je, Hasabou, Nahla, Nuthethi, Rishita, Tiu, Ramon, Levis, Mark, Perl, Alexander, Larson, Richard, Podoltsev, Nikolai, Strickland, Stephen, Wang, Eunice, Atallah, Ehab, and Schiller, Gary

Subjects
Acute myelogenous leukemia, FLT3 inhibitor, FLT3 mutation, Hematopoietic stem cell transplantation, Post-transplantation maintenance therapy, Adult, Humans, fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Aniline Compounds, Recurrence
Abstract

The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib improved the survival of patients with relapsed or refractory (R/R) FLT3-mutated acute myelogenous leukemia (AML) in the phase 3 ADMIRAL trial. In this study, we assessed survival and relapse rates of patients in the ADMIRAL trial who underwent hematopoietic stem cell transplantation (HSCT), as well as safety outcomes in patients who received post-transplantation gilteritinib maintenance therapy. ADMIRAL was a global phase 3 randomized controlled trial that enrolled adult patients with FLT3-mutated R/R AML. Patients with R/R AML who harbored FLT3 internal tandem duplication mutations in the juxtamembrane domain or D835/I836 point mutations in the tyrosine kinase domain were randomized (2:1) to gilteritinib (120 mg/day) or to preselected high- or low-intensity salvage chemotherapy (1 or 2 cycles). Patients in the gilteritinib arm who proceeded to HSCT could receive post-transplantation gilteritinib maintenance therapy if they were within 30 to 90 days post-transplantation and had achieved composite complete remission (CRc) with successful engraftment and no post-transplantation complications. Adverse events (AEs) during HSCT were recorded in the gilteritinib arm only. Survival outcomes and the cumulative incidence of relapse were assessed in patients who underwent HSCT during the trial. Treatment-emergent AEs were evaluated in patients who restarted gilteritinib as post-transplantation maintenance therapy. Patients in the gilteritinib arm underwent HSCT more frequently than those in the chemotherapy arm (26% [n = 64] versus 15% [n = 19]). For all transplantation recipients, 12- and 24-month overall survival (OS) rates were 68% and 47%, respectively. Despite a trend toward longer OS after pretransplantation CRc, post-transplantation survival was comparable in the 2 arms. Patients who resumed gilteritinib after HSCT had a low relapse rate after pretransplantation CRc (20%) or CR (0%). The most common AEs observed with post-transplantation gilteritinib therapy were increased alanine aminotransferase level (45%), pyrexia (43%), and diarrhea (40%); grade ≥3 AEs were related primarily to myelosuppression. The incidences of grade ≥III acute graft-versus-host disease and related mortality were low. Post-transplantation survival was similar across the 2 study arms in the ADMIRAL trial, but higher remission rates with gilteritinib facilitated receipt of HSCT. Gilteritinib as post-transplantation maintenance therapy had a stable safety and tolerability profile and was associated with low relapse rates. Taken together, these data support a preference for bridging therapy with gilteritinib over chemotherapy in transplantation-eligible patients.

Published
2023

9. Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials

Author

Dixon, Bradley P., Kavanagh, David, Aris, Alvaro Domingo Madrid, Adams, Brigitte, Kang, Hee Gyung, Wang, Edward, Garlo, Katherine, Ogawa, Masayo, Amancha, Praveen, Chakravarty, Sourish, Heyne, Nils, Kim, Seong Heon, Cataland, Spero, Yoon, Sung-Soo, Miyakawa, Yoshitaka, Luque, Yosu, Muff-Luett, Melissa, Tanaka, Kazuki, and Greenbaum, Larry A.

Published
2024
Full Text
View/download PDF

12. Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma

Author

Koh, Youngil, Kim, Hyemin, Joo, So Young, Song, Seulki, Choi, Young Hoon, Kim, Hyung Rae, Moon, Byul, Byun, Jamin, Hong, Junshik, Shin, Dong-Yeop, Park, Solip, Lee, Kwang Hyuck, Lee, Kyu Taek, Lee, Jong Kyun, Park, Daechan, Lee, Se-Hoon, Jang, Jin-Young, Lee, Hyunsook, Kim, Jung-Ae, Yoon, Sung-Soo, and Park, Joo Kyung

Published
2023
Full Text
View/download PDF

14. Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation

Author

Baek, Dong Won, Moon, Joon Ho, Lee, Jae Hoon, Kang, Ka-Won, Lee, Ho Sup, Eom, Hyeon-Seok, Lee, Enuyoung, Lee, Ji Hyun, Lee, Jeong-Ok, Park, Seong Kyu, Kim, Seok Jin, Yoo, Keon Hee, Yoon, Sung-Soo, Koh, Youngil, Kang, Hyoung Jin, Won, Jong-Ho, Lyu, Chuhl Joo, Hahn, Seung Min, Lee, Jung-Hee, Park, Joon Seong, Jo, Jae-Cheol, Mun, Yeung-Chul, Yang, Deok-Hwan, Song, Ga-Young, Lim, Sung-Nam, and Sohn, Sang Kyun

Published
2023
Full Text
View/download PDF

22. Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX

Author

Spencer, Andrew, Moreau, Philippe, Mateos, Maria-Victoria, Goldschmidt, Hartmut, Suzuki, Kenshi, Levin, Mark-David, Sonneveld, Pieter, Orlowski, Robert Z., Yoon, Sung-Soo, Usmani, Saad Z., Weisel, Katja, Reece, Donna, Ahmadi, Tahamtan, Pei, Huiling, Mayo, Wendy Garvin, Gai, Xue, Carey, Jodi, Bartlett, J. Blake, Carson, Robin, and Dimopoulos, Meletios A.

Published
2024
Full Text
View/download PDF

26. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

Author

Bartlett, Nancy L., Assouline, Sarit, Giri, Pratyush, Schuster, Stephen J., Cheah, Chan Y., Matasar, Matthew, Gregory, Gareth P., Yoon, Dok Hyun, Shadman, Mazyar, Fay, Keith, Yoon, Sung-Soo, Panizo, Carlos, Flinn, Ian, Johnston, Anna, Bosch, Francesc, Sehn, Laurie H., Wei, Michael C., Yin, Shen, To, Iris, Li, Chi-Chung, Huang, Huang, Kwan, Antonia, Penuel, Elicia, and Budde, Lihua E.

Published
2023
Full Text
View/download PDF

28. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study

Author

Gerds, Aaron T, Verstovsek, Srdan, Vannucchi, Alessandro M, Al-Ali, Haifa Kathrin, Lavie, David, Kuykendall, Andrew T, Grosicki, Sebastian, Iurlo, Alessandra, Goh, Yeow Tee, Lazaroiu, Mihaela C, Egyed, Miklos, Fox, Maria Laura, McLornan, Donal, Perkins, Andrew, Yoon, Sung-Soo, Gupta, Vikas, Kiladjian, Jean-Jacques, Granacher, Nikki, Lee, Sung-Eun, Ocroteala, Luminita, Passamonti, Francesco, Harrison, Claire N, Oh, Stephen, Klencke, Barbara J, Yu, Jing, Donahue, Rafe, Kawashima, Jun, and Mesa, Ruben

Published
2023
Full Text
View/download PDF

31. Single-cell analysis of AIMP2 splice variants informs on drug sensitivity and prognosis in hematologic cancer

Author

Ku, Jayoung, Kim, Ryul, Kim, Dongchan, Kim, Daeyoon, Song, Seulki, Lee, Keonyong, Lee, Namseok, Kim, MinA, Yoon, Sung-Soo, Kwon, Nam Hoon, Kim, Sunghoon, Kim, Yoosik, and Koh, Youngil

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Genetics, Cancer, Hematology, Childhood Leukemia, Pediatric Cancer, Rare Diseases, Pediatric, 5.1 Pharmaceuticals, Aetiology, 2.1 Biological and endogenous factors, Development of treatments and therapeutic interventions, Adolescent, Adult, Aged, Aged, 80 and over, Alternative Splicing, Cell Line, Tumor, Drug Resistance, Neoplasm, Exons, Female, Gene Expression Regulation, Neoplastic, Hematologic Neoplasms, Humans, Image Processing, Computer-Assisted, In Situ Hybridization, Fluorescence, Leukemia, Myeloid, Acute, Male, Middle Aged, Molecular Targeted Therapy, Nuclear Proteins, Paclitaxel, Prognosis, Single-Cell Analysis, Young Adult, Biological sciences, Biomedical and clinical sciences
Abstract

Aminoacyl-tRNA synthetase-interacting multifunctional protein 2 (AIMP2) is a non-enzymatic component required for the multi-tRNA synthetase complex. While exon 2 skipping alternatively spliced variant of AIMP2 (AIMP2-DX2) compromises AIMP2 activity and is associated with carcinogenesis, its clinical potential awaits further validation. Here, we found that AIMP2-DX2/AIMP2 expression ratio is strongly correlated with major cancer signaling pathways and poor prognosis, particularly in acute myeloid leukemia (AML). Analysis of a clinical patient cohort revealed that AIMP2-DX2 positive AML patients show decreased overall survival and progression-free survival. We also developed targeted RNA-sequencing and single-molecule RNA-FISH tools to quantitatively analyze AIMP2-DX2/AIMP2 ratios at the single-cell level. By subclassifying hematologic cancer cells based on their AIMP2-DX2/AIMP2 ratios, we found that downregulating AIMP2-DX2 sensitizes cells to anticancer drugs only for a subgroup of cells while it has adverse effects on others. Collectively, our study establishes AIMP2-DX2 as a potential biomarker and a therapeutic target for hematologic cancer.

Published
2020

32. A database of 5305 healthy Korean individuals reveals genetic and clinical implications for an East Asian population

Author

Lee, Jeongeun, Lee, Jean, Jeon, Sungwon, Lee, Jeongha, Jang, Insu, Yang, Jin Ok, Park, Soojin, Lee, Byungwook, Choi, Jinwook, Choi, Byung-Ok, Gee, Heon Yung, Oh, Jaeseong, Jang, In-Jin, Lee, Sanghyuk, Baek, Daehyun, Koh, Youngil, Yoon, Sung-Soo, Kim, Young-Joon, Chae, Jong-Hee, Park, Woong-Yang, Bhak, Jong Hwa, and Choi, Murim

Published
2022
Full Text
View/download PDF

33. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Author

Abulafia, Adi Shacham, Al-Ali, Haifa Kathrin, Andreasson, Bjorn, Angona, Anna, Ayala, Rosa, Bang, Soo-Mee, Bank, Bruce, Barraco, Fiorenza, Beggiato, Eloise, Benghiat, Fleur Samantha, Bonifacio, MassimiliaNo, Bories, Claire, Borsaru, Gabriela, Brabrand, Mette, Braester, Andrei, Broliden, Andes, Buxhofer-Ausch, Veronika, Cambier, Nathalie, Caramella, Marianna, Carpentier, Benjamin, Cascavilla, Nicola, Castellano, Maria Giraldo, Chang, Hung, Chen, Chih-Cheng, Cheong, June-Won, Choi, Yunsuk, Choi, Philip, Corsetti, Maria Teresa, Cuadrado, Isabel Montero, Cunningham, Julia, Damaj, Gandhi Laurent, De Stefano, Valerio, Delage, Robert, Delgado, Regina Garcĺa, Diaz, Jose Miguel Torregrosa, Dombi, Péter, Dubruille, Viviane, Egyed, Miklós, El Fassi, Daniel, Elinder-Camburn, Anna, Elli, Elena Maria, Ellis, Martin, Fava, Carmen, Fazal, Salman, Fleischman, Angela, Foltz, Lynda, Fox, Laura, Gabrail, Nashat, Garcĺa-Gutiérrez, Jose Valentĺn, Gerds, Aaron, Girault, Stephane, Gisslinger, Heinz, Gluvacov, Alexandru, Goh, Yeow Tee, Göthert, Joachim, Granacher, Nikki, Grosicki, Sebastian, Gupta, Vikas, Hadjiev (Hadzhiev), Evgeni (Evgueniy), Hafraoui, Kaoutar, Hamed, Aryan, Harrison, Claire, Hasselbalch, Hans, Hauser, Hanns, Heaney, Mark, Hebart, Holger, Hernandez Rivas, Jesus Maria, Higuero Saavedra, Victor, Hillis, Christopher, Hou, Hsin-An, How, Jonathan, Huang, Daniel, Hus, Marek, Illés, Arpad, Isidori, Alessandro, Iurlo, Alessandra, Ivanov, Vadim, Johansson, Peter, Jung, Chul Won, Kiladjian, Jean-Jacques, Kirgner, Ilya, Koren-Michowitz, Maya, Koschmieder, Steffen, Kosztolanyi, Szabolcs Ors, Kreiniz, Natalia, Kuykendall, Andrew, Lambert, Jonathan, Laribi, Kamel, Lascaux, Axelle, Lavie, Noa, Lavie, David, Lazaroiu, Mihaela, Leahy, Michael, Lech-Maranda, Ewa, Lee, Sung-Eun, Lee, Won Sik, Legrand, Ollivier, Lemoli, Roberto, Liang, James, Lim, Sung-Nam, Loschi, Michael, Lucchesi, Alessandro, Macarie, Ioan, Marolleau, Jean-Pierre, Martelli, Maurizio, Mayer, Jiri, McCloskey, James, McDermott, Christopher, McLornan, Donal, McMahon, Brandon, Mehta, Priyanka, Mesa, Ruben, Mikala, Gábor, Milojkovic, Dragana, Mineur, Philippe, Mishchenko, Elena, Moon, Joon Ho, Nagy, Zsolt, Narayanan, Srinivasan, O'Connell, Casey, Ocroteala, Luminita, Oh, Stephen, Ojeda-Uribe, Mario, Ong, Kiat Hoe, Otegbeye, Folashade, Palmer, Jeanne, Pane, Fabrizio, Passamonti, Francesco, Patriarca, Andrea, Perkins, Andrew, Pietrantuono, Giuseppe, Plander, Mark, Platzbecker, Uwe, Prasad, Ritam, Prejzner, Witold, Rachow, Tobias, Radinoff, Atanas, Rejtő, László, Rinaldi, Ciro, Robak, Tadeusz, Rodriguez, Maria Angeles Fernandez, Ronson, Aaron, Ross, David, Sacha, Tomasz, Sadjadian, Parvis, Salar, Antonio, Santillana, Guillermo Sanz, Scheid, Christof, Schmidt, Aline, Severinsen, Marianne Tang, Stoeva, Vera, Szwedyk, Paweł, Tiribelli, Mario, Trautmann-Grill, Karolin, Trottier, Amy, Tzvetkov, Nikolay, van Droogenbroeck, Janusz, Vannucchi, Alessandro, Verstovsek, Srdan, Vianelli, Nicola, von Bubnoff, Nikolas, Wolf, Dominik, Woszczyk, Dariusz, Woźny, Tomasz, Wróbel, Tomasz, Xicoy, Blanca, Yeh, Su-Peng, Yoon, Sung-Soo, Gerds, Aaron T, Vannucchi, Alessandro M, Kuykendall, Andrew T, Lazaroiu, Mihaela C, Egyed, Miklos, Fox, Maria Laura, Harrison, Claire N, Klencke, Barbara J, Ro, Sunhee, Donahue, Rafe, and Kawashima, Jun

Published
2023
Full Text
View/download PDF

34. Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study

Author

Lee, Ji Hyun, primary, Choi, Jimin, additional, Min, Chang-Ki, additional, Park, Sung-Soo, additional, Jo, Jae-Cheol, additional, Lee, Yoo Jin, additional, Kim, Jin Seok, additional, Eom, Hyeon-Seok, additional, Jung, Jongheon, additional, Moon, Joon Ho, additional, Cho, Hee Jeong, additional, Lee, Myung-won, additional, Yoon, Sung-Soo, additional, Byun, Ja Min, additional, Lee, Jae Hoon, additional, Lee, Je-Jung, additional, Jung, Sung-Hoon, additional, Shin, Ho-Jin, additional, Kim, Do Young, additional, Yi, Jun Ho, additional, Lee, Seung-Shin, additional, Do, Young Rok, additional, Yoon, Dok Hyun, additional, Cho, Hyungwoo, additional, Lee, Won Sik, additional, Lee, Ho Sup, additional, Uhm, Jieun, additional, Kim, Hyo Jung, additional, Jang, Hee Ryeong, additional, Kim, Sung-Hyun, additional, and Kim, Kihyun, additional

Published
2024
Full Text
View/download PDF

35. Glofitamab combined with poseltinib and lenalidomide for relapsed/refractory diffuse large B cell lymphoma: Interim analysis of GPL study.

Author

Koh, Youngil, primary, Byun, Ja Min, additional, Hong, Junshik, additional, Lim, Sung-nam, additional, Kim, Seok Jin, additional, Kong, Jee Hyun, additional, Lee, Gyeong-Won, additional, Kim, Hyo Jung, additional, Kim, Da Jung, additional, Lee, Jeong-Ok, additional, Park, Young-Hun, additional, Yoon, Dok Hyun, additional, Yoo, Kwai Han, additional, Kang, Hye Jin, additional, Yang, Deok-Hwan, additional, Kwak, Jae-Yong, additional, Kwon, Jung Hye, additional, Kang, Ka Won, additional, Baek, Dong Won, additional, and Yoon, Sung-Soo, additional

Published
2024
Full Text
View/download PDF

41. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial

Author

Konopleva, Marina Y., Röllig, Christoph, Cavenagh, Jamie, Deeren, Dries, Girshova, Larisa, Krauter, Jürgen, Martinelli, Giovanni, Montesinos, Pau, Schäfer, Jonas A., Ottmann, Oliver, Petrini, Mario, Pigneux, Arnaud, Rambaldi, Alessandro, Recher, Christian, Rodriguez-Veiga, Rebeca, Taussig, David, Vey, Norbert, Yoon, Sung-Soo, Ott, Marion, Muehlbauer, Susanne, Beckermann, Benjamin M., Catalani, Olivier, Genevray, Magali, Mundt, Kirsten, Jamois, Candice, Fenaux, Pierre, and Wei, Andrew H.

Published
2022
Full Text
View/download PDF

42. Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Author

Perl, Alexander E., Larson, Richard A., Podoltsev, Nikolai A., Strickland, Stephen, Wang, Eunice S., Atallah, Ehab, Schiller, Gary J., Martinelli, Giovanni, Neubauer, Andreas, Sierra, Jorge, Montesinos, Pau, Récher, Christian, Yoon, Sung-Soo, Hosono, Naoko, Onozawa, Masahiro, Chiba, Shigeru, Kim, Hee-Je, Hasabou, Nahla, Lu, Qiaoyang, Tiu, Ramon, and Levis, Mark J.

Published
2022
Full Text
View/download PDF

47. Unraveling the impact of lysosomal dysfunction on myeloproliferative neoplasm.

Author

Yoon, Hyundong, Lee, Dohoon, Song, Seulki, Koo, Bonil, Park, Jihyun, Kim, Tae Kon, Kim, Sun, Kim, Sheehyun, Hong, Junshik, Byun, Ja Min, Shin, Dong‐Yeop, Kim, Inho, Koh, Youngil, and Yoon, Sung‐Soo

Subjects
LYSOSOMAL storage diseases, POLYCYTHEMIA vera, MYELOPROLIFERATIVE neoplasms, LOGISTIC regression analysis, RNA sequencing
Abstract

Background: Lysosomal dysfunction (LD) impacts cytokine regulation, inflammation, and immune responses, influencing the development and progression of cancer. Inflammation is implicated in the pathogenesis of myeloproliferative neoplasm (MPN). With a hypothesis that LD significantly contributes to MPN carcinogenesis by inducing abnormal inflammation, our objective was to elucidate the pathophysiological mechanisms of MPN arising from an LD background. Methods: Genotyping of the LD background was performed in a cohort of MPN patients (n = 190) and healthy controls (n = 461). Logistic regression modeling, utilizing genotype data, was employed to estimate the correlation between LD and MPN. Whole transcriptome sequencing (WTS) (LD carriers = 8, non‐carriers = 6) and single‐cell RNA sequencing data (LD carriers = 2, non‐carriers = 2, healthy controls = 2) were generated and analyzed. Results: A higher variant frequency of LD was observed in MPN compared to healthy controls (healthy, 4.9%; MPN, 7.8%), with the highest frequency seen in polycythemia vera (PV) (odds ratio = 2.33, p = 0.03). WTS revealed that LD carriers exhibited upregulated inflammatory cytokine ligand–receptor genes, pathways, and network modules in MPNs compared to non‐carriers. At the single‐cell level, there was monocyte expansion and elevation of cytokine ligand–receptor interactions, inflammatory transcription factors, and network modules centered on monocytes. Notably, Oncostatin‐M (OSM) consistently emerged as a candidate molecule involved in the pathogenesis of LD‐related PV. Conclusions: In summary, an LD background is prevalent in MPN patients and leads to increased cytokine dysregulation and inflammation. OSM, as one of the potential molecules, plays a crucial role in PV pathogenesis by impairing lysosomal function. Lysosomal dysfunction (LD) impacts cytokine regulation, inflammation, and immune responses, influencing the development and progression of cancer. Inflammation is implicated in the pathogenesis of myeloproliferative neoplasm (MPN). With a hypothesis that LD significantly contributes to MPN carcinogenesis by inducing abnormal inflammation, our objective was to elucidate the pathophysiological mechanisms of MPN arising from an LD background. Genotyping of the LD background was performed in a cohort of MPN patients (n = 190) and healthy controls (n = 461). Logistic regression modeling, utilizing genotype data, was employed to estimate the correlation between LD and MPN. Whole transcriptome sequencing (WTS) (LD carriers = 8, non‐carriers = 6) and single‐cell RNA‐sequencing data (LD carriers = 2, non‐carriers = 2, healthy controls = 2) were generated and analyzed. A higher variant frequency of LD was observed in MPN compared to healthy controls (healthy, 4.9%; MPN, 7.8%), with the highest frequency seen in polycythemia vera (PV) (odds ratio = 2.33, p = 0.03). WTS revealed that LD carriers exhibited upregulated inflammatory cytokine ligand‐receptor genes, pathways, and network modules in MPNs compared to non‐carriers. At the single‐cell level, there was monocyte expansion and elevation of cytokine ligand‐receptor interactions, inflammatory transcription factors, and network modules centered on monocytes. Notably, Oncostatin‐M (OSM) consistently emerged as a candidate molecule involved in the pathogenesis of LD‐related PV. In summary, an LD background is prevalent in MPN patients and leads to increased cytokine dysregulation and inflammation. OSM may play a crucial role in PV pathogenesis by impairing lysosomal function. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. Comparative analysis of single versus tandem autologous stem cell transplantation in patients with multiple myeloma in Korea: the KMM2102 study

Author

Jung, Jongheon, primary, Jung, Sung-Hoon, additional, Lee, Je-Jung, additional, Do, Young Rok, additional, Kang, Ka-Won, additional, Lee, Jung Lim, additional, Yoon, Sung-Soo, additional, Min, Chang-Ki, additional, Kang, Hye Jin, additional, Lee, Ji Hyun, additional, Park, Ju-Hyun, additional, Kim, Kihyun, additional, and Eom, Hyeon-Seok, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results